Rodent Myasthenia Gravis (MG) Models

Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by antibodies that destroy communication between nerves and muscles, leading to weakness of skeletal muscles, particularly those controlling the eyes, mouth, throat, and limbs. The disease is caused by autoantibodies against acetylcholine receptors (AChR) at the neuromuscular junction. HKeyBio offers a well-validated experimental autoimmune myasthenia gravis (EAMG) model induced by immunization with R97-116 peptide (corresponding to region 97-116 of the rat AChR α subunit). This model recapitulates key human MG features including muscle weakness, elevated anti-AChR antibodies, and neuromuscular junction pathology, providing a robust platform for preclinical efficacy testing of novel MG therapeutics.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Clinically relevant – R97-116 peptide induced EAMG closely mimics human MG with antibody-mediated pathology and muscle weakness.

Well-characterized endpoints – Body weight, muscle strength (grip strength test), serum anti-AChR antibody levels (ELISA), muscle histopathology (H&E).

Translational value – Ideal for testing immunomodulators, FcRn inhibitors, complement inhibitors, and antigen-specific therapies.

Species options – Available in both Lewis rat and C57BL/6 mouse strains.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

ATechnical Data & Validation

R97-116 peptides Induced MG Model

Applications

• Efficacy testing of immunomodulators (corticosteroids, mycophenolate, cyclosporine), FcRn inhibitors, complement inhibitors (anti-C5), and biologics

• Target validation for AChR antibody-mediated pathology

• Biomarker discovery (anti-AChR antibodies, complement factors)

• Mechanism of action (MOA) studies for autoimmune neuromuscular disorders

• IND-enabling pharmacology studies

Model Specifications

Parameter	Rat MG Model	Mouse MG Model
Species/Strain	Lewis rat	C57BL/6 mouse
Induction method	Immunization with R97-116 peptide (AChR α subunit 97-116) in CFA, with booster immunizations
Study duration	4–8 weeks	4–8 weeks
Key endpoints	Body weight, muscle strength (grip strength), serum anti-AChR antibody titers, muscle histopathology (H&E), neuromuscular junction analysis (optional)	Body weight, muscle strength, serum anti-AChR antibodies
Data package	Raw data, analysis reports, grip strength measurements, ELISA data, histology slides, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What is the R97-116 peptides induced MG model?

A1: It is an experimental autoimmune myasthenia gravis (EAMG) model established by immunizing animals with R97-116 peptides. It recapitulates the pathological features of human myasthenia gravis, an autoimmune disease damaging neuromuscular transmission.

Q2: What animal species are used for this MG model?

A2: We adopt C57BL/6 mice and Lewis rats to build the R97-116 peptides induced MG model. Both are well-recognized tools for preclinical MG research.

Q3: What evaluation indicators are applied in the model assessment?

A3: We monitor multiple indicators including body weight, muscle strength, serum anti-AChR antibody level and muscle histopathology via H&E staining for comprehensive evaluation.

Q4: What is the modeling cycle and key timeline?

A4: The modeling starts with R97-116 peptide immunization on Day 0. Relevant observations and detections will last until Day 70 to assess the progression of MG symptoms.

Q5: What are the main applications and advantages of this MG model?

A5: This stable and reproducible model perfectly simulates the pathogenesis of human MG. It is ideal for efficacy screening and mechanism research of novel drugs and therapeutic strategies against myasthenia gravis.